Stock Price Quote

SUN PHARMACEUTICAL INDUSTRIES LTD.

NSE : SUNPHARMABSE : 524715ISIN CODE : INE044A01036Industry : Pharmaceuticals & DrugsHouse : Sun Pharma
BSE1735.803.95 (+0.23 %)
PREV CLOSE ( ) 1731.85
OPEN PRICE ( ) 1732.25
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 64159
TODAY'S LOW / HIGH ( )1726.00 1747.85
52 WK LOW / HIGH ( )1547.25 1910
NSE1737.405.3 (+0.31 %)
PREV CLOSE( ) 1732.10
OPEN PRICE ( ) 1734.50
BID PRICE (QTY) 1737.40 (184)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 1727602
TODAY'S LOW / HIGH( ) 1725.40 1747.80
52 WK LOW / HIGH ( )1548 1910
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 01-03 1993
Management Info
Dilip S Shanghvi - Chairman Kirti Ganorkar - Managing Director
Registered Office

Address Sun Pharma Advanced Research Centre (S P A R C),Tandalja, ,
Vadodara,
Gujarat-390012

Phone 0265- 5515500 / 5515600 / 5515700

Email secretarial@sunpharma.com

Website www.sunpharma.com

Registrars Details
MUFG Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE

NEWS

11Nov Sun Pharmaceutical Industries informs
Pursuant to Regulation 30 of the Securities and Exchange Board of India..
06Nov Sun Pharmaceutical Industries reports
Sun Pharmaceutical Industries has reported result for second quarter end..
26Sep Pharma stocks tumble after US imposes
Indian pharmaceutical stocks declined after US President Donald Trump's..
10Sep Sun Pharmaceutical’s Halol facility ge
U.S. Food and Drug Administration (USFDA) has classified Sun Pharmaceuti..
10Sep Sun Pharmaceutical Industries informs
Sun Pharmaceutical Industries has informed that it enclosed Disclosure u..

Financials

in Millions
QTR Sep 25 ANNUAL 25
Net Profit5642.242826.2
Gross Profit 6717.5 50305.7
Operating Profit 12563.871620.5
Net Sales 45481.1230033.3

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Sanofi Cons. Health (BSE)
peergroup  4986.40 (7.07%)
M.Cap ( in Cr)11483.99
Kwality Pharma (BSE)
peergroup  971.40 (10.24%)
M.Cap ( in Cr)1007.94
Divi's Lab (BSE)
peergroup  6589.65 (1.08%)
M.Cap ( in Cr)174934.50
Strides Pharma Scien (BSE)
peergroup  973.80 (5.44%)
M.Cap ( in Cr)8975.78
Emcure Pharma (BSE)
peergroup  1380.60 (3.10%)
M.Cap ( in Cr)26171.32

Shareholding Pattern

NON-INSTITUTION 8.73%
FI/BANKS/INSURANCE 6.04%
PROMOTERS 54.48%
MUTUAL FUNDS/UTI 12.41%
GOVERNMENT 0%
FII 0%

About Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries Ltd. was incorporated in the year 1993. Its today's share price is 1735.8. Its current market capitalisation stands at Rs 416476.56 Cr. In the latest quarter, company has reported Gross Sales of Rs. 230033.3 Cr and Total Income of Rs.236273 Cr. The company's management includes Kirti Ganorkar, Vidhi Shanghvi, Aalok Shanghvi, Rama Bijapurkar, Gautam Doshi, Rolf Hoffmann, Pawan Goenka, Dilip S Shanghvi, Dilip S Shanghvi, Anoop Deshpande.

It is listed on the BSE with a BSE Code of 524715 , NSE with an NSE Symbol of SUNPHARMA and ISIN of INE044A01036. It's Registered office is at Sun Pharma Advanced Research Centre (S P A R C),Tandalja, Vadodara-390012, Gujarat. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Deloitte Haskins & Sells, Deloittee Haskins & Sells, Price Waterhouse, SRBC & Co LLP

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.